Incyte (NASDAQ:INCY) Stock Gets Price Target Trim from Wells Fargo & Company

Incyte (NASDAQ:INCY) had its price objective cut by Wells Fargo & Company from $128.00 to $127.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective points to a potential upside of 4.91% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. Royal Bank Of Canada upped their price target on shares of Incyte from $114.00 to $117.00 and gave the company a “sector perform” rating in a research report on Friday. Morgan Stanley initiated coverage on shares of Incyte in a research report on Tuesday, October 20th. They set an “equal weight” rating and a $119.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of Incyte in a research report on Tuesday. Wall Street Zen cut shares of Incyte from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Finally, UBS Group set a $152.00 price objective on shares of Incyte in a research report on Friday. Twelve research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $132.90.

Incyte Price Performance

Shares of INCY traded up $4.25 during trading hours on Friday, reaching $121.06. 1,076,579 shares of the company’s stock traded hands, compared to its average volume of 1,730,010. Incyte has a twelve month low of $89.25 and a twelve month high of $132.60. The firm has a market capitalization of $24.54 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 4.83 and a beta of 0.74. The business’s fifty day simple moving average is $120.62 and its two-hundred day simple moving average is $108.07.

Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. The company had revenue of $1.56 billion during the quarter, compared to analyst estimates of $1.46 billion. Incyte had a net margin of 27.71% and a return on equity of 29.93%. The business’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.26 EPS. On average, equities research analysts expect that Incyte will post 1.97 EPS for the current year.

Insider Buying and Selling at Incyte

In other news, insider Pablo Cagnoni sold 2,642 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $112.71, for a total transaction of $297,779.82. Following the completion of the transaction, the insider owned 183,200 shares of the company’s stock, valued at approximately $20,648,472. The trade was a 1.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 16.20% of the company’s stock.

Institutional Investors Weigh In On Incyte

A number of hedge funds have recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund grew its stake in shares of Incyte by 1.5% during the third quarter. Oregon Public Employees Retirement Fund now owns 20,970 shares of the biopharmaceutical company’s stock worth $2,545,000 after buying an additional 300 shares during the last quarter. Gallacher Capital Management LLC bought a new position in shares of Incyte during the 3rd quarter worth approximately $218,000. IPG Investment Advisors LLC acquired a new position in shares of Incyte during the third quarter valued at about $1,779,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Incyte during the third quarter worth approximately $1,123,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Incyte during the third quarter worth about $7,498,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Barclays raised its price target on Incyte from $139 to $143 and maintained an “overweight” rating, implying substantial upside from recent levels. Barclays analyst rating
• Positive Sentiment: Third-quarter revenue beat expectations. Incyte reported $1.56 billion in total revenue, up 14% year over year and above the $1.46 billion analyst consensus. Product demand was broad-based: Jakafi and Jakafi XR sales rose 4% to $827 million, Opzelura sales increased 36% to $255 million, and hematology and oncology portfolio sales climbed 38% to $235 million. Incyte Q3 results
• Positive Sentiment: Management increased its 2026 outlook. Full-year net-sales guidance was raised to $5.21 billion-$5.30 billion from $5.13 billion-$5.26 billion previously, while Opzelura guidance was lifted to $1.10 billion-$1.12 billion. The stronger outlook reinforces expectations for continued commercial momentum. Incyte raises 2026 guidance
• Neutral Sentiment: Analyst views remain mixed. One Seeking Alpha analysis upgraded Incyte to “hold,” arguing that recent ESMO-related developments had largely closed the valuation gap, while other analysts—including Barclays and Guggenheim—remain constructive. Incyte valuation analysis
• Negative Sentiment: Incyte posted a quarterly loss after recording a $1.23 billion in-process research and development charge tied to its Vega Therapeutics acquisition. The company reported a loss of $3.60 per share, although this was narrower than analysts expected and largely reflected the acquisition accounting charge. Incyte Q3 acquisition charge

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.